



www.genfit.com

GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF JUNE 26, 2012

- All resolutions approved by a large majority of the shareholders
- Promising perspectives for the signing of a major industrial partnership

Lille (France), Cambridge (Massachusetts, United States), July 2, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the approval of all the resolutions submitted to the combined shareholders' meeting held on June 26th, 2012 in Lille (France).

The shareholders approved all the resolutions proposed by the Management Board by a large majority of least 81% of the cast votes.

In particular, the shareholders approved the corporate and consolidated financial statements for the 2011 financial year, and authorized GENFIT's Management to perform one or more financial operations, if necessary to strengthen the Company's equity position.

During this combined shareholders' meeting, the Management Board notably stated that:

- as of June 30, 2012, the cash and cash equivalents of the Company amounted to approximately € 10.9 million, as compared to € 12.8 million on December 31st, 2011,
- GFT505 continues its development according to plan. The Company expects to receive authorization from the Food & Drug Administration (FDA) in September for the US launch of the Phase IIb study of GFT505 in NASH,
- there is a strong probability of the imminent signing of a partnership with a major pharmaceutical company, based on one of GENFIT's proprietary programs.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian

Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr